Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study.
Bandiera C, Locatelli I, Courlet P, Cardoso E, Zaman K, Stravodimou A, Dolcan A, Sarivalasis A, Zurcher JP, Aedo-Lopez V, Dotta-Celio J, Peters S, Guidi M, Wagner AD, Csajka C, Schneider MP.
Bandiera C, et al. Among authors: dolcan a.
Cancers (Basel). 2023 Jan 3;15(1):316. doi: 10.3390/cancers15010316.
Cancers (Basel). 2023.
PMID: 36612312
Free PMC article.